Results 91 to 100 of about 8,893 (235)

Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials [PDF]

Background: Increasing evidence suggests that GLP-1 receptor agonists (GLP-1RA) have a potential use in addiction treatment. Few studies have assessed the impact of GLP-1RA on substance use disorder (SUD), particularly in humans.
Longaroni, Mattia, Martinelli, Silvia, Mazzotta, Alessandro, Petrucciani, Niccolo   +3 more
core   +1 more source

Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes

Frontiers in Pharmacology
Background: Diabetes affects millions of people worldwide annually, and several methods, including medications, are used for its management; glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one such class of medications.
Yongru Chen, Jingxian Chen, Jingxian Chen, Shuo Zhang, Shuo Zhang, Dan Zhu, Feiying Deng, Feiying Deng, Rui Zuo, Yufei Hu, Yue Zhao, Yale Duan, Benwei Lin, Fengwu Chen, Yun Liang, Jiaxiong Zheng, Barkat Ali Khan, Kaijian Hou   +17 more
doaj   +1 more source

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi, Anetzberger, Anichini, Aoyama, Baggio, Balint, Ban, Beckman, Bouxsein, Brunton, Chen, Coleman, Dempster, Ealey, Eckel, Feng, Flatt, Friedman, Griffith, Griffith, Hamilton, Hu, Karim, Kim, Lee, Lu, Ma, Mabilleau, Mabilleau, Mansur, Marenzana, Mieczkowska, Napoli, Nuche-Berenguer, Nuche-Berenguer, Nuche-Berenguer, Nystrom, Nystrom, Odgaard, Okerson, Orland, Orriss, Paschalis, Pereira, Pereira, Prisby, Richard, Roche, Roszer, Schalkwijk, Scheller, Selley, Shymkiw, Smits, Stabley, Sun, Tartaglia, Upadhyay, van Bloemendaal, Vijan, Williams, Wu, Yamamoto, Yamamoto, Yamamoto   +64 more
core   +6 more sources

Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP

Drug Design, Development and Therapy, 2023
Ping Fang,1 Zhengqin Ye,1 Ran Li,1 Dunmin She,2 Guannan Zong,1 Liya Zhang,1 Ying Xue,1 Keqin Zhang1 1Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People’s Republic of China ...
Fang P, Ye Z, Li R, She D, Zong G, Zhang L, Xue Y, Zhang K   +7 more
doaj  

Fixed ratio combinations GLP-1RA and basal insulin: literature review

Problems of Endocrinology
The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia’s risk.
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Ju. V. Gorbunova, E. V. Volotova, A. I. Robertus, I. E. Makarenko, V. B. Saparova, R. V. Drai, V. I. Petrov   +10 more
openaire   +2 more sources

Comparing SGLT2i and Other Oral Antidiabetic Drugs as Dual Therapy Add‐On to Metformin in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
This systematic literature review and meta‐analysis compared sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) against other metformin‐containing oral dual‐therapies (ODTs) in type 2 diabetes mellitus. SGLT‐2i plus metformin exhibited overall comparable efficacy and safety, with a lower risk of hypoglycaemia and greater weight reduction than other ...
Yuhang Ma, Yi Lin, Xiaoying Ding, Yongde Peng   +3 more
wiley   +1 more source

Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations

Diabetology & Metabolic Syndrome
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the ...
Baixuan Shen, Wanying Wang, Yuanhui Guo, Zilong Chen, Chuanxin Liu, Jiarui Huang, Ying Li   +6 more
doaj   +1 more source

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.

PLoS ONE, 2020
BACKGROUND:We investigated changes in clinical characteristics of SGLT2i and GLP-1RA real-world initiators in Denmark before/after landmark cardiovascular outcome trials.
Jakob S Knudsen, Lisbeth M Baggesen, Maria Lajer, Larisa Nurkanovic, Anastasia Ustyugova, Henrik T Sørensen, Reimar W Thomsen   +6 more
doaj   +1 more source

Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2 [PDF]

BACKGROUND AND PURPOSE: Cardiovascular outcome trials demonstrate that glucagonlike peptide-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes (T2D), whereas dipeptidyl peptidase-4 ...
Andersen, Grethe, Hastrup, Sidsel, Hedegaard, Jakob Nebeling, Johnsen, Soren Paaske, Rungby, Jørgen   +4 more
core   +2 more sources

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1915-1923, March 2026.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source